Thu. 28 Mar 2024, 8:56am ET
Benzinga
Earnings, News
Iterum Therapeutics (NASDAQ:ITRM) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.94) by 13.83 percent. This is a 55.77 percent decrease over losses of $(0.52) per share from the same period last year.